Neurodegeneration in Niemann-Pick type C disease and Huntington's disease: Impact of defects in membrane trafficking

Current Drug Targets

Volumn 10, Issue 7, 2009, Pages 653-665

  Schweitzer, J K ^a   Krivda, J P ^a   D'Souza Schorey, C ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CEP 1347; HUNTINGTIN; LIVER X RECEPTOR AGONIST; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NIEMANN PICK TYPE C1 PROTEIN; NIEMANN PICK TYPE C2 PROTEIN; RETINOID X RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

CELL DEATH; CELL TRANSPORT; CHOLESTEROL METABOLISM; DRUG MECHANISM; ENZYME INHIBITION; GENE MUTATION; HUNTINGTON CHOREA; LIPID STORAGE; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROPROTECTION; NIEMANN PICK DISEASE; NONHUMAN; PHENOTYPE; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; SYNAPTOGENESIS; TRANSPORT VESICLE; ANIMAL; CELL MEMBRANE; CELL SURVIVAL; HUMAN; METABOLISM; NERVE CELL; NERVE FIBER TRANSPORT; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; AXONAL TRANSPORT; CELL MEMBRANE; CELL SURVIVAL; HUMANS; HUNTINGTON DISEASE; NERVE DEGENERATION; NEURONS; NIEMANN-PICK DISEASE, TYPE C; TRANSPORT VESICLES;

EID: 70249145840     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009788680437     Document Type: Review

References (150)

1. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA. Molecular pathways to neurodegeneration. Nat Med 2004; 10 Suppl: S2-9.
2. Kazantsev AG. Cellular pathways leading to neuronal dysfunction and degeneration. Drug News Perspect 2007; 20: 501-509
3. Vanier MT, Millat G. Niemann-Pick disease type C. Clin Genet 2003; 64: 269-281
4. Ikonen E, Holtta-Vuori M. Cellular pathology of Niemann-Pick type C disease. Semin Cell Dev Biol 2004; 15: 445-454
5. Cruz JC, Chang TY. Fate of endogenously synthesized cholesterol in Niemann-Pick type C1 cells. J Biol Chem 2000; 275: 41309-41316
6. Chen W, Sun Y, Welch C, Gorelik A, Leventhal AR, Tabas I, et al. Preferential ATP-binding cassette transporter A1-mediated cholesterol efflux from late endosomes/lysosomes. J Biol Chem 2001; 276: 43564-43569 (Pubitemid 37383915)
7. Choi HY, Karten B, Chan T, Vance JE, Greer WL, Heidenreich RA, et al. Impaired ABCA1-dependent lipid efflux and hypoalphalipoproteinemia in human Niemann-Pick type C disease. J Biol Chem 2003; 278: 32569-32577 (Pubitemid 37059094)
8. Wang MD, Franklin V, Sundaram M, Kiss RS, Ho K, Gallant M, et al. Differential regulation of ATP binding cassette protein A1 expression and ApoA-I lipidation by Niemann-Pick type C1 in murine hepatocytes and macrophages. J Biol Chem 2007; 282: 22525-22533 (Pubitemid 47267343)
9. Espenshade PJ, Hughes AL. Regulation of sterol synthesis in eukaryotes. Annu Rev Genet 2007; 41: 401-427
10. Underwood KW, Jacobs NL, Howley A, Liscum L. Evidence for a cholesterol transport pathway from lysosomes to endoplasmic reticulum that is independent of the plasma membrane. J Biol Chem 1998; 273: 4266-4274 (Pubitemid 28103299)
11. Liscum L, Sturley SL. Intracellular trafficking of Niemann-Pick C proteins 1 and 2: obligate components of subcellular lipid transport. Biochim Biophys Acta 2004; 1685: 22-27
12. Infante RE, Abi-Mosleh L, Radhakrishnan A, Dale JD, Brown MS, Goldstein JL. Purified NPC1 protein. I. Binding of cholesterol and oxysterols to a 1278-amino acid membrane protein. J Biol Chem 2008; 283: 1052-1063
13. Infante RE, Wang ML, Radhakrishnan A, Kwon HJ, Brown MS, Goldstein JL. NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and lipid bilayers, a step in cholesterol egress from lysosomes. Proc Natl Acad Sci U S A 2008; 105: 15287-15292
14. Infante RE, Radhakrishnan A, Abi-Mosleh L, Kinch LN, Wang ML, Grishin NV, et al. Purified NPC1 protein: II. Localization of sterol binding to a 240-amino acid soluble luminal loop. J Biol Chem 2008; 283: 1064-1075
15. Subramanian K, Balch WE. NPC1/NPC2 function as a tag team duo to mobilize cholesterol. Proc Natl Acad Sci USA 2008; 105: 15223-15224
16. Gelsthorpe ME, Baumann N, Millard E, Gale SE, Langmade SJ, Schaffer JE, et al. Niemann-Pick type C1 I1061T mutant encodes a functional protein that is selected for endoplasmic reticulum-associated degradation due to protein misfolding. J Biol Chem 2008; 283: 8229-8236
17. Simons K, Gruenberg J. Jamming the endosomal system: lipid rafts and lysosomal storage diseases. Trends Cell Biol 2000; 10: 459-462
18. Vance JE, Hayashi H, Karten B. Cholesterol homeostasis in neurons and glial cells. Semin Cell Dev Biol 2005; 16: 193-212. (Pubitemid 40432121)
19. Liu B, Li H, Repa JJ, Turley SD, Dietschy JM. Genetic variations and treatments that affect the lifespan of the NPC1 mouse. J Lipid Res 2008; 49: 663-669
20. Li H, Turley SD, Liu B, Repa JJ, Dietschy JM. GM2/GD2 and GM3 gangliosides have no effect on cellular cholesterol pools or turnover in normal or NPC1 mice. J Lipid Res 2008; 49: 1816-1828
21. Zervas M, Somers KL, Thrall MA, Walkley SU. Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr Biol 2001; 11: 1283-1287 (Pubitemid 32774086)
22. Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007; 6: 765-772 (Pubitemid 47238662)
23. Galanaud D, Tourbah A, Lehericy S, Leveque N, Heron B, Billette de Villemeur T, et al. 24 month-treatment with miglustat of three patients with Niemann-Pick disease type C: follow up using brain spectroscopy. Mol Genet Metab 2009; 96: 55-58
24. Lloyd-Evans E, Morgan AJ, He X, Smith DA, Elliot-Smith E, Sillence DJ, et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat Med 2008; 14: 1247-1255
25. Liscum L, Faust JR. The intracellular transport of low density lipoprotein-derived cholesterol is inhibited in Chinese hamster ovary cells cultured with 3-beta-[2-(diethylamino)ethoxy]androst-5-en-17-one. J Biol Chem 1989; 264: 11796-11806 (Pubitemid 19185347)
26. Kobayashi T, Beuchat MH, Lindsay M, Frias S, Palmiter RD, Sakuraba H, et al. Late endosomal membranes rich in lysobisphosphatidic acid regulate cholesterol transport. Nat Cell Biol 1999; 1: 113-118
27. Mukherjee S, Maxfield FR. Lipid and cholesterol trafficking in NPC. Biochim Biophys Acta 2004; 1685: 28-37.
28. Garver WS, Jelinek D, Francis GA, Murphy BD. The Niemann-Pick C1 gene is downregulated by feedback inhibition of the SREBP pathway in human fibroblasts. J Lipid Res 2008; 49: 1090-1102
29. Patel SC, Suresh S, Kumar U, Hu CY, Cooney A, Blanchette-Mackie EJ, et al. Localization of Niemann-Pick C1 protein in astrocytes: implications for neuronal degeneration in Niemann-Pick type C disease. Proc Natl Acad Sci U S A 1999; 96: 1657-1662 (Pubitemid 29098507)
30. Patterson MC, Platt F. Therapy of Niemann-Pick disease, type C. Biochim Biophys Acta 2004; 1685: 77-82.
31. Schmitz G, Langmann T. Transcriptional regulatory networks in lipid metabolism control ABCA1 expression. Biochim Biophys Acta 2005; 1735: 1-19.
32. Boadu E, Francis GA. The role of vesicular transport in ABCA1-dependent lipid efflux and its connection with NPC pathways. J Mol Med 2006; 84: 266-275
33. Repa JJ, Li H, Frank-Cannon TC, Valasek MA, Turley SD, Tansey MG, et al. Liver X receptor activation enhances cholesterol loss from the brain, decreases neuroinflammation, and increases survival of the NPC1 mouse. J Neurosci 2007; 27: 14470-14480
34. Wojtal K, Trojnar MK, Czuczwar SJ. Endogenous neuroprotective factors: neurosteroids. Pharmacol.Rep. 2006; 58: 335-340
35. Mellon SH, Gong W, Schonemann MD. Endogenous and synthetic neurosteroids in treatment of Niemann-Pick Type C disease. Brain Res Rev 2008; 57: 410-420
36. Langmade SJ, Gale SE, Frolov A, Mohri I, Suzuki K, Mellon SH, et al. Pregnane X receptor (PXR) activation: a mechanism for neuroprotection in a mouse model of Niemann-Pick C disease. Proc Natl Acad Sci USA 2006; 103: 13807-13812
37. Zhang M, Dwyer NK, Love DC, Cooney A, Comly M, Neufeld E, et al. Cessation of rapid late endosomal tubulovesicular trafficking in Niemann-Pick type C1 disease. Proc Natl Acad Sci U S A 2001; 98: 4466-4471 (Pubitemid 32295000)
38. Ko DC, Gordon MD, Jin JY, Scott MP. Dynamic movements of organelles containing Niemann-Pick C1 protein: NPC1 involvement in late endocytic events. Mol Biol Cell 2001; 12: 601-614
39. Lebrand C, Corti M, Goodson H, Cosson P, Cavalli V, Mayran N, et al. Late endosome motility depends on lipids via the small GTPase Rab7. EMBO J 2002; 21: 1289-1300
40. Ganley IG, Pfeffer SR. Cholesterol accumulation sequesters Rab9 and disrupts late endosome function in NPC1-deficient cells. J Biol Chem 2006; 281: 17890-17899
41. Mayran N, Parton RG, Gruenberg J. Annexin II regulates multivesicular endosome biogenesis in the degradation pathway of animal cells. EMBO J 2003; 22: 3242-3253
42. Pagano RE. Endocytic trafficking of glycosphingolipids in sphingolipid storage diseases. Philos Trans R Soc Lond B Biol Sci 2003; 358: 885-891 (Pubitemid 36639713)
43. Wastney ME, Pentchev PG, Neufeld EB. Fitting a mathematical model to biological data: intracellular trafficking in Niemann-Pick C disease. Adv Exp Med Biol 2003; 537: 63-75.
44. Zerial M, McBride H. Rab proteins as membrane organizers. Nat Rev Mol Cell Biol 2001; 2: 107-117
45. Choudhury A, Dominguez M, Puri V, Sharma DK, Narita K, Wheatley CL, et al. Rab proteins mediate Golgi transport of caveola-internalized glycosphingolipids and correct lipid trafficking in Niemann-Pick C cells. J Clin Invest 2002; 109: 1541-1550 (Pubitemid 34663516)
46. Narita K, Choudhury A, Dobrenis K, Sharma DK, Holicky EL, Marks DL, et al. Protein transduction of Rab9 in Niemann-Pick C cells reduces cholesterol storage. Faseb J 2005; 19: 1558-1560 (Pubitemid 41279030)
47. Walter M, Davies JP, Ioannou YA. Telomerase immortalization upregulates Rab9 expression and restores LDL cholesterol egress from Niemann-Pick C1 late endosomes. J Lipid Res 2003; 44: 243-253 (Pubitemid 37287767)
48. Kaptzan T, West SA, Holicky EL, Wheatley CL, Marks DL, Wang T, et al. Development of a Rab9 transgenic mouse and its ability to increase the lifespan of a murine model of Niemann-Pick type C disease. Am J Pathol 2009; 174: 14-20.
49. Choudhury A, Sharma DK, Marks DL, Pagano RE. Elevated endosomal cholesterol levels in Niemann-Pick cells inhibit rab4 and perturb membrane recycling. Mol Biol Cell 2004; 15: 4500-4511 (Pubitemid 39299099)
50. Pipalia NH, Hao M, Mukherjee S, Maxfield FR. Sterol, protein and lipid trafficking in Chinese hamster ovary cells with Niemann-Pick type C1 defect. Traffic 2007; 8: 130-141 (Pubitemid 46100000)
51. Holtta-Vuori M, Tanhuanpaa K, Mobius W, Somerharju P, Ikonen E. Modulation of cellular cholesterol transport and homeostasis by Rab11. Mol Biol Cell 2002; 13: 3107-3122 (Pubitemid 35034249)
52. Henry L, Sheff DR. Rab8 regulates basolateral secretory, but not recycling, traffic at the recycling endosome. Mol Biol Cell 2008; 19: 2059-2068
53. Linder MD, Uronen RL, Holtta-Vuori M, van der Sluijs P, Peranen J, Ikonen E. Rab8-dependent recycling promotes endosomal cholesterol removal in normal and sphingolipidosis cells. Mol Biol Cell 2007; 18: 47-56. (Pubitemid 46066709)
54. Hao M, Lin SX, Karylowski OJ, Wustner D, McGraw TE, Maxfield FR. Vesicular and non-vesicular sterol transport in living cells. The endocytic recycling compartment is a major sterol storage organelle. J Biol Chem 2002; 277: 609-617 (Pubitemid 34952098)
55. Valenza M, Cattaneo E. Cholesterol dysfunction in neurodegenerative diseases: is Huntington's disease in the list? Prog Neurobiol 2006; 80: 165-176
56. Karten B, Vance DE, Campenot RB, Vance JE. Cholesterol accumulates in cell bodies, but is decreased in distal axons, of Niemann-Pick C1-deficient neurons. J Neurochem 2002; 83: 1154-1163 (Pubitemid 35407407)
57. Karten B, Vance DE, Campenot RB, Vance JE. Trafficking of cholesterol from cell bodies to distal axons in Niemann Pick C1-deficient neurons. J Biol Chem 2003; 278: 4168-4175 (Pubitemid 36801154)
58. Wasser CR, Ertunc M, Liu X, Kavalali ET. Cholesterol-dependent balance between evoked and spontaneous synaptic vesicle recycling. J Physiol 2007; 579: 413-429.
59. Liscum L. Niemann-Pick type C mutations cause lipid traffic jam. Traffic 2000; 1: 218-225
60. Vainio S, Bykov I, Hermansson M, Jokitalo E, Somerharju P, Ikonen E. Defective insulin receptor activation and altered lipid rafts in Niemann-Pick type C disease hepatocytes. Biochem J 2005; 391: 465-472 (Pubitemid 41634772)
61. Wu C, Cui B, He L, Chen L, Mobley WC. The coming of age of axonal neurotrophin signaling endosomes. J Proteom 2009; 72: 46-55.
62. Henderson LP, Lin L, Prasad A, Paul CA, Chang TY, Maue RA. Embryonic striatal neurons from niemann-pick type C mice exhibit defects in cholesterol metabolism and neurotrophin responsiveness. J Biol Chem 2000; 275: 20179-20187
63. Bronfman FC, Escudero CA, Weis J, Kruttgen A. Endosomal transport of neurotrophins: roles in signaling and neurodegenerative diseases. Dev.Neurobiol. 2007; 67: 1183-1203 (Pubitemid 47229867)
64. Hartmann T, Kuchenbecker J, Grimm MO. Alzheimer's disease: the lipid connection. J Neurochem 2007; 103 Suppl 1: 159-170
65. Michikawa M. Neurodegenerative disorders and cholesterol. Curr Alzheimer Res 2004; 1: 271-275
66. Kins S, Lauther N, Szodorai A, Beyreuther K. Subcellular trafficking of the amyloid precursor protein gene family and its pathogenic role in Alzheimer's disease. Neurodegener Dis 2006; 3: 218-226 (Pubitemid 44600307)
67. Jin LW, Shie FS, Maezawa I, Vincent I, Bird T. Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am J Pathol 2004; 164: 975-985 (Pubitemid 38235479)
68. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998; 57: 369-384
69. Martin JB, Gusella JF. Huntington's disease. Pathogenesis and management. N Engl J Med 1986; 315: 1267-1276
70. Chiu E, Alexander L. Causes of death in Huntington's disease. Med J Aust 1982; 1: 153.
71. Myers RH. Huntington's disease genetics. NeuroRx 2004; 1: 255-262
72. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993; 72: 971-983 (Pubitemid 23110238)
73. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP,Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44: 559-577
74. Albin RL, Reiner A, Anderson KD, Dure LS,4th, Handelin B, Balfour R, et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann Neurol 1992; 31: 425-430
75. Kassubek J, Gaus W, Landwehrmeyer GB. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2004; 62: 523-4; author reply 524.
76. Lunkes A, Mandel JL. A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum Mol Genet 1998; 7: 1355-1361
77. Hackam AS, Singaraja R, Wellington CL, Metzler M, McCutcheon K, Zhang T, et al. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol 1998; 141: 1097-1105
78. Gil JM, Rego AC. Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci 2008; 28: 2156.
79. Tai HC, Schuman EM. Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nat Rev Neurosci 2008; 9: 826-838
80. Roze E, Betuing S, Deyts C, Vidailhet M, Caboche J. Pathophysiology of Huntington's disease: An update. Rev Neurol 2008; 164: 977-994
81. Duennwald ML, Lindquist S. Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity. Genes Dev 2008; 22: 3308-3319
82. Peters PJ, Ning K, Palacios F, Boshans RL, Kazantsev A, Thompson LM, et al. Arfaptin 2 regulates the aggregation of mutant huntingtin protein. Nat Cell Biol 2002; 4: 240-245 (Pubitemid 34218198)
83. Rangone H, Pardo R, Colin E, Girault JA, Saudou F, Humbert S. Phosphorylation of arfaptin 2 at Ser260 by Akt Inhibits PolyQ-huntingtin-induced toxicity by rescuing proteasome impairment. J Biol Chem 2005; 280: 22021-22028
84. Wyttenbach A, Carmichael J, Swartz J, Furlong RA, Narain Y, Rankin J, et al. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci U S A 2000; 97: 2898-2903
85. Perrin V, Regulier E, Abbas-Terki T, Hassig R, Brouillet E, Aebischer P, et al. Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease. Mol Ther 2007; 15: 903-911 (Pubitemid 46621648)
86. Wacker JL, Zareie MH, Fong H, Sarikaya M, Muchowski PJ. Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nat.Struct.Mol.Biol. 2004; 11: 1215-1222
87. Tagawa K, Marubuchi S, Qi ML, Enokido Y, Tamura T, Inagaki R, et al. The induction levels of heat shock protein 70 differentiate the vulnerabilities to mutant huntingtin among neuronal subtypes. J Neurosci 2007; 27: 868-880 (Pubitemid 46174507)
88. Gong B, Lim MC, Wanderer J, Wyttenbach A, Morton AJ. Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death. Brain Res Bull 2008; 75: 146-157. (Pubitemid 350297653)
89. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004; 431: 805-810 (Pubitemid 39434070)
90. Valenza M, Cattaneo E. Cholesterol dysfunction in neurodegenerative diseases: is Huntington's disease in the list? Prog Neurobiol 2006; 80: 165-176
91. Dietschy JM, Turley SD. Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 2004; 45: 1375-1397
92. Wilson JD, Lindsey CA, Dietschy JM. Influence of dietary cholesterol on cholesterol metabolism. Ann N Y Acad Sci 1968; 149: 808-821
93. Pfrieger FW. Cholesterol homeostasis and function in neurons of the central nervous system. Cell Mol Life Sci 2003; 60: 1158-1171 (Pubitemid 36791918)
94. Sipione S, Rigamonti D, Valenza M, Zuccato C, Conti L, Pritchard J, et al. Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum Mol Genet 2002; 11: 1953-1965 (Pubitemid 34919271)
95. Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, Jamot L, et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci 2005; 25: 9932-9939 (Pubitemid 41528031)
96. Valenza M, Leoni V, Tarditi A, Mariotti C, Bjorkhem I, Di Donato S, et al. Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2007; 28: 133-142 (Pubitemid 47429978)
97. Valenza M, Carroll JB, Leoni V, Bertram LN, Bjorkhem I, Singaraja RR, et al. Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Hum Mol Genet 2007; 16: 2187-2198 (Pubitemid 47354901)
98. Leoni V, Mariotti C, Tabrizi SJ, Valenza M, Wild EJ, Henley SM, et al. Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. Brain 2008; 131: 2851-2859
99. Nasir J, Floresco SB, O'Kusky JR, Diewert VM, Richman JM, Zeisler J, et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995; 81: 811-823
100. Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell R, Phansalkar A, et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet. 2007; 3: e82.
101. Li XJ, Li SH, Sharp AH, Nucifora FC,Jr, Schilling G, Lanahan A, et al. A huntingtin-associated protein enriched in brain with implications for pathology. Nature 1995; 378: 398-402.
102. Wanker EE, Rovira C, Scherzinger E, Hasenbank R, Walter S, Tait D, et al. HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system. Hum Mol Genet 1997; 6: 487-495 (Pubitemid 27116471)
103. Mills IG, Gaughan L, Robson C, Ross T, McCracken S, Kelly J, et al. Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors. J Cell Biol 2005; 170: 191-200. (Pubitemid 41043802)
104. Harjes P, Wanker EE. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci 2003; 28: 425-433 (Pubitemid 36976745)
105. Pal A, Severin F, Lommer B, Shevchenko A, Zerial M. Huntingtin-HAP40 complex is a novel Rab5 effector that regulates early endosome motility and is up-regulated in Huntington's disease. J Cell Biol 2006; 172: 605-618 (Pubitemid 43243880)
106. Peters PJ, Gao M, Gaschet J, Ambach A, van Donselaar E, Traverse JF, et al. Characterization of coated vesicles that participate in endocytic recycling. Traffic 2001; 2: 885-895 (Pubitemid 33100582)
107. Williams A, Jahreiss L, Sarkar S, Saiki S, Menzies FM, Ravikumar B, et al. Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. Curr Top Dev Biol 2006; 76: 89-101. (Pubitemid 44760539)
108. Ravikumar B, Duden R, Rubinsztein DC. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet 2002; 11: 1107-1117 (Pubitemid 34521091)
109. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004; 36: 585-595 (Pubitemid 38715985)
110. Ravikumar B, Imarisio S, Sarkar S, O'Kane CJ, Rubinsztein DC. Rab5 modulates aggregation and toxicity of mutant huntingtin through macroautophagy in cell and fly models of Huntington disease. J Cell Sci 2008; 121: 1649-1656
111. Borrell-Pages M, Zala D, Humbert S, Saudou F. Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. Cell Mol Life Sci 2006; 63: 2642-2660 (Pubitemid 44800717)
112. Gauthier LR, Charrin BC, Borrell-Pages M, Dompierre JP, Rangone H, Cordelieres FP, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004; 118: 127-138 (Pubitemid 38902819)
113. Li SH, Gutekunst CA, Hersch SM, Li XJ. Interaction of huntingtin-associated protein with dynactin P150Glued. J Neurosci 1998; 18: 1261-1269
114. Warby SC, Chan EY, Metzler M, Gan L, Singaraja RR, Crocker SF, et al. Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Hum Mol Genet 2005; 14: 1569-1577 (Pubitemid 40823464)
115. Rangone H, Poizat G, Troncoso J, Ross CA, MacDonald ME, Saudou F, et al. The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Eur J Neurosci 2004; 19: 273-279 (Pubitemid 38177866)
116. Zala D, Colin E, Rangone H, Liot G, Humbert S, Saudou F. Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum Mol Genet 2008; 17: 3837-3846 (Pubitemid 352762847)
117. Colin E, Zala D, Liot G, Rangone H, Borrell-Pages M, Li XJ, et al. Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. EMBO J 2008; 27: 2124-2134
118. Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol 2007; 81: 294-330. (Pubitemid 46528643)
119. Strand AD, Baquet ZC, Aragaki AK, Holmans P, Yang L, Cleren C, et al. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci 2007; 27: 11758-11768 (Pubitemid 350006916)
120. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001; 293: 493-498 (Pubitemid 32679077)
121. Timmusk T, Palm K, Lendahl U, Metsis M. Brain-derived neurotrophic factor expression in vivo is under the control of neuron-restrictive silencer element. J Biol Chem 1999; 274: 1078-1084
122. Shimojo M, Hersh LB. REST/NRSF-interacting LIM domain protein, a putative nuclear translocation receptor. Mol Cell Biol 2003; 23: 9025-9031 (Pubitemid 37499793)
123. Shimojo M. Huntingtin regulates RE1-silencing transcription factor/neuron-restrictive silencer factor (REST/NRSF) nuclear trafficking indirectly through a complex with REST/NRSF-interacting LIM domain protein (RILP) and dynactin p150 Glued. J Biol Chem 2008; 283: 34880-34886
124. Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 2003; 35: 76-83. (Pubitemid 37048599)
125. Chen ZY, Ieraci A, Teng H, Dall H, Meng CX, Herrera DG, et al. Sortilin controls intracellular sorting of brain-derived neurotrophic factor to the regulated secretory pathway. J Neurosci 2005; 25: 6156-6166 (Pubitemid 40923482)
126. Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hempstead BL, et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 2004; 24: 4401-4411 (Pubitemid 38608151)
127. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257-269 (Pubitemid 36144114)
128. del Toro D, Canals JM, Gines S, Kojima M, Egea G, Alberch J. Mutant huntingtin impairs the post-Golgi trafficking of brain-derived neurotrophic factor but not its Val66Met polymorphism. J Neurosci 2006; 26: 12748-12757 (Pubitemid 44904570)
129. Alberch J, Lopez M, Badenas C, Carrasco JL, Mila M, Munoz E, et al. Association between BDNF Val66Met polymorphism and age at onset in Huntington disease. Neurology 2005; 65: 964-965 (Pubitemid 41362158)
130. Kalb R. The protean actions of neurotrophins and their receptors on the life and death of neurons. Trends Neurosci 2005; 28: 5-11. (Pubitemid 40038796)
131. Levy YS, Gilgun-Sherki Y, Melamed E, Offen D. Therapeutic potential of neurotrophic factors in neurodegenerative diseases. BioDrugs 2005; 19: 97-127. (Pubitemid 40559475)
132. Ranen NG, Lipsey JR, Treisman G, Ross CA. Sertraline in the treatment of severe aggressiveness in Huntington's disease. J Neuropsychiatry Clin Neurosci 1996; 8: 338-340 (Pubitemid 26275747)
133. Slaughter JR, Martens MP, Slaughter KA. Depression and Huntington's disease: prevalence, clinical manifestations, etiology, and treatment. CNS Spectr. 2001; 6: 306-326 (Pubitemid 32574137)
134. Peng Q, Masuda N, Jiang M, Li Q, Zhao M, Ross CA, et al. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp Neurol 2008; 210: 154-163
135. Apostol BL, Illes K, Pallos J, Bodai L, Wu J, Strand A, et al. Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum Mol Genet 2006; 15: 273-285 (Pubitemid 43125981)
136. Perrin V, Dufour N, Raoul C, Hassig R, Brouillet E, Aebischer P, et al. Implication of the JNK pathway in a rat model of Huntington's disease. Exp Neurol 2009; 215: 191-200.
137. Cheung EC, Slack RS. Emerging role for ERK as a key regulator of neuronal apoptosis. Sci.STKE 2004; 2004: PE45.
138. Chu C, Alapat D, Wen X, Timo K, Burstein D, Lisanti M, et al. Ectopic expression of murine diphosphoinositol polyphosphate phosphohydrolase 1 attenuates signaling through the ERK1/2 pathway. Cell Signal 2004; 16: 1045-1059 (Pubitemid 38798055)
139. McKay MM, Morrison DK. Integrating signals from RTKs to ERK/MAPK. Oncogene 2007; 26: 3113-3121
140. Apostol BL, Simmons DA, Zuccato C, Illes K, Pallos J, Casale M, et al. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. Mol Cell Neurosci 2008; 39: 8-20.
141. Colucci-D'Amato L, Perrone-Capano C, di Porzio U. Chronic activation of ERK and neurodegenerative diseases. Bioessays 2003; 25: 1085-1095 (Pubitemid 37411768)
142. Lievens JC, Woodman B, Mahal A, Bates GP. Abnormal phosphorylation of synapsin I predicts a neuronal transmission impairment in the R6/2 Huntington's disease transgenic mice. Mol Cell Neurosci 2002; 20: 638-648
143. Junttila MR, Li SP, Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 2008; 22: 954-965
144. Truant R, Atwal R, Burtnik A. Hypothesis: Huntingtin may function in membrane association and vesicular trafficking. Biochem Cell Biol 2006; 84: 912-917
145. De Vos KJ, Grierson AJ, Ackerley S, Miller CC. Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci 2008; 31: 151-173
146. Nixon RA. Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases. Neurobiol Aging 2005; 26: 373-382
147. Kim C, Lee SJ. Controlling the mass action of alpha-synuclein in Parkinson's disease. J Neurochem 2008; 107: 303-316
148. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006; 313: 324-328 (Pubitemid 44480951)
149. Nonis D, Schmidt MH, van de Loo S, Eich F, Dikic I, Nowock J, et al. Ataxin-2 associates with the endocytosis complex and affects EGF receptor trafficking. Cell Signal 2008; 20: 1725-1739
150. Chang TY, Chang CC, Ohgami N, Yamauchi Y. Cholesterol sensing, trafficking, and esterification. Annu Rev Cell Dev Biol 2006; 22: 129-157